C07K 16/2875
Against the ngf/tnf superfamily
Official title: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
C07K16/2875 (Against the ngf/tnf superfamily) appears on 821 US grants and 1,673 published applications in this corpus.
Search patents in C07K- Granted patents
- 821
- Published applications
- 1,673
- Assignees
- 554
- Inventors
- 2,706
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 10 | 0 |
| 2000 | 11 | 0 |
| 2001 | 11 | 6 |
| 2002 | 12 | 36 |
| 2003 | 24 | 50 |
| 2004 | 12 | 28 |
| 2005 | 8 | 40 |
| 2006 | 14 | 44 |
| 2007 | 13 | 32 |
| 2008 | 12 | 36 |
| 2009 | 18 | 43 |
| 2010 | 21 | 55 |
| 2011 | 25 | 51 |
| 2012 | 21 | 70 |
| 2013 | 30 | 52 |
| 2014 | 30 | 63 |
| 2015 | 36 | 55 |
| 2016 | 45 | 88 |
| 2017 | 50 | 85 |
| 2018 | 40 | 75 |
| 2019 | 43 | 60 |
| 2020 | 52 | 94 |
| 2021 | 53 | 102 |
| 2022 | 57 | 89 |
| 2023 | 44 | 110 |
| 2024 | 49 | 102 |
| 2025 | 45 | 113 |
| 2026 | 26 | 94 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- TL1A-binding molecules, IL-23p19-binding molecules, and bispecific antigen-binding molecules, and uses thereof1 Sep 2026US 12,723,093 B2Newsoara Biopharmaceutical Technology (Suzhou) Co., Ltd.
- Anti-idiotype antibody molecules and uses thereof25 Aug 2026US 12,715,934 B2Otsuka Pharmaceutical Co., Ltd.
- Antibody constant region variant11 Aug 2026US 12,703,738 B2Chugai Seiyaku Kabushiki Kaisha
- NGF antagonists for medical use11 Aug 2026US 12,703,753 B2Elanco US Inc.
- Novel Use of Anti-BLyS Antibodies8 Oct 2026US 2026/0308266 A1GlaxoSmithKline Intellectual Property Limited
- Compositions and Methods for Genetically Modifying CD708 Oct 2026US 2026/0308580 A1Intellia Therapeutics, Inc.
- Antibodies and uses thereof1 Oct 2026US 2026/0297188 A1LTZ Therapeutics Inc.
- Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases1 Oct 2026US 2026/0297206 A1Fortvita Biologics Inc.
- Anti-tl1a×il23 bispecific antibodies and their applications thereof1 Oct 2026US 2026/0297207 A1Simcere Pharmaceutical Co., Ltd.
Most cited
By later US patents
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Human antibodies derived from immunized xenomice1,057US 6,075,181 AAbgenix, Inc. · 2000
- Human antibodies derived from immunized xenomice943US 6,150,584 AAbgenix, Inc. · 2000
- Generation of xenogeneic antibodies639US 6,114,598 AAbgenix, Inc. · 2000
- Generation of Xenogenetic antibodies561US 6,162,963 AAbgenix, Inc. · 2000